Cancer Family
Thymus Epithelial Neoplasm
CI-CAN-00000365Explore in graph →
Non-malignant39 active trials1 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000365Explore in graph →
Clinical trials
136 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06980077 | Ivonescimab for the Treatment of Thymic Cancer | recruiting | Phase 2 | 25 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06248515 | A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors | recruiting | Phase 2 | 18 | Georgetown UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05104736 |
| PT-112 in Subjects With Thymoma and Thymic Carcinoma |
| recruiting |
| Phase 2 |
| 53 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Aug 28, 2026 |
| clinicaltrials |
| NCT07324629 | Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma | recruiting | Phase 2 | 30 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07691619 | Hypofractionated Radiotherapy After Complete Resection for Stage II/III Thymic Epithelial Tumors(TET-HFRT40) | recruiting | Phase 2 | 49 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07598955 | Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma(SELECT-NK-THYM) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT06019468 | Neoadjuvant Treatment For Locally Advanced Thymic Cancer | recruiting | Phase 2 | 25 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06838910 | Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma | recruiting | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT06186726 | Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors | recruiting | Phase 2 | 48 | Jian ChenOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT06311955 | Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor | recruiting | Phase 2 | 48 | Jian ChenOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT06311968 | The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor | recruiting | Phase 2 | 55 | Jian ChenOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT06730308 | Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma | recruiting | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05832827 | First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)(Artemis) | recruiting | Phase 2 | 35 | National Cancer Center, JapanOTHER_GOV | 1 | Oct 23, 2023 | clinicaltrials |
Data updated 5 days agoSource updated Sep 21, 2026source: clinicaltrials